Nabbing PG Biotech, Qiagen Gets Assays, Sales Network in Crucial Asia Market; Focuses on Dx | GenomeWeb

Qiagen's decision to acquire Chinese molecular diagnostics company Shenzhen PG Biotech for $14.5 million in cash, disclosed this week, will provide the company with more than 10 assays approved by the Chinese State Food and Drug Administration, more than 20 employees focused on assay development, and an established sales channel and regulatory expertise in the Chinese market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.